Xencor, Inc. (NASDAQ:XNCR) announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10, Morningstar.com reports. The firm had revenue of $13.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%.
Shares of Xencor (XNCR) opened at 19.94 on Friday. Xencor has a 52 week low of $18.45 and a 52 week high of $29.38. The company has a 50-day moving average of $22.56 and a 200 day moving average of $23.00. The firm’s market capitalization is $935.70 million.
A number of brokerages recently weighed in on XNCR. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research note on Saturday, April 29th. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 target price on shares of Xencor in a research note on Tuesday, August 8th. BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Xencor in a research note on Tuesday, June 6th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $29.33.
COPYRIGHT VIOLATION NOTICE: “Xencor, Inc. (XNCR) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS” was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/xencor-inc-xncr-releases-quarterly-earnings-results-beats-expectations-by-0-10-eps-updated.html.
In other Xencor news, major shareholder John S. Stafford III acquired 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 28th. The shares were bought at an average price of $19.94 per share, with a total value of $119,640.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder John S. Stafford III purchased 1,500 shares of the stock in a transaction on Friday, June 16th. The shares were purchased at an average cost of $19.67 per share, for a total transaction of $29,505.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 182,035 shares of company stock worth $3,728,456 and sold 34,766 shares worth $739,408. Company insiders own 4.03% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Alps Advisors Inc. increased its position in shares of Xencor by 0.3% in the second quarter. Alps Advisors Inc. now owns 20,102 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 52 shares in the last quarter. Falcon Point Capital LLC increased its position in shares of Xencor by 0.5% in the second quarter. Falcon Point Capital LLC now owns 29,082 shares of the biopharmaceutical company’s stock valued at $614,000 after buying an additional 156 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Xencor by 0.6% in the first quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock valued at $867,000 after buying an additional 209 shares in the last quarter. Legal & General Group Plc increased its position in shares of Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its position in shares of Xencor by 2.3% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock valued at $492,000 after buying an additional 521 shares in the last quarter. 73.53% of the stock is currently owned by institutional investors and hedge funds.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.